ArticleNPJ breast cancer2023

The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer.

Albert Grinshpun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.